Close

Sorrento Therapeutics (SRNE) Closes Acquisition of Majority Stake in Scilex Pharma

Go back to Sorrento Therapeutics (SRNE) Closes Acquisition of Majority Stake in Scilex Pharma

Sorrento Therapeutics Closes Acquisition of Scilex

November 8, 2016 4:20 PM EST

SAN DIEGO, Nov. 8, 2016 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento") and Scilex Pharmaceuticals Inc. ("SCILEX") announced today the closing of a transaction by which Sorrento acquired a majority of SCILEX.  Sorrento acquired approximately 72% of the outstanding common stock of SCILEX for a net purchase price of up to approximately $47.6 million, payable in a combination of cash and shares of Sorrento common stock.  Further, the U.S. Food & Drug Administration ("FDA") recently provided clear feedback related to the resubmission of the new drug application ("NDA") for SCILEX's lead product candidate, ZTlido (lidocaine patch 1.8%), a branded lidocaine patch... More